Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a common antibiotic keep nasal polyps from coming back?

NCT ID NCT07780292

Disease control Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 21, 2026 · Last updated Aug 21, 2026

Summary

This trial asks whether taking low-dose oral azithromycin after sinus surgery can lower the chance of nasal polyps returning in people with chronic rhinosinusitis. Adults with severe disease who have had functional endoscopic sinus surgery will receive either azithromycin three times a week plus nasal rinses, or just nasal rinses, for 12 weeks. The goal is to see if the drug's anti-inflammatory effects help control long-term inflammation and reduce recurrence.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
oral azithromycin (low dose, 500 mg three times weekly) plus routine nasal douching
What this could lead to
If effective, this could offer a simple, low-cost way to reduce nasal polyp regrowth after sinus surgery, potentially delaying or avoiding repeat operations.
What could go wrong
This is a small, single-center trial, and results may not apply broadly. Azithromycin can cause gastrointestinal side effects and, rarely, heart rhythm issues or antibiotic resistance.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 52 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • Adult patients of both sexes aged ≥ 18 years. * Documented clinical and radiological diagnosis of Chronic Rhinosinusitis with Nasal Polyps (CRSWNP). * Patients with high baseline disease severity scores based on: * CT Paranasal Sinuses Staging: High Lund-Mackay CT Score. * Symptom Burden Assessment: High SNOT-22 Questionnaire Score. • Patients who comply with scheduled follow-up visits and appointments. Exclusion Criteria: * • Patients aged under 18 years (\< 18 years). * Presence of unilateral nasal polyps, antrochoanal polyps, granuloma / granulomatous lesions, fungal * rhinosinusitis, or suspected benign or malignant sinonasal neoplasms. * Development of significant drug-related adverse effects, adverse reactions, or clinical complications during the * treatment course. * Known hypersensitivity or previous severe allergic reactions to macrolide antibiotics. * Baseline prolonged QTc interval, active cardiac arrhythmias, or significant cardiovascular disease. * Pre-existing significant impairment of hepatic or renal functions. * Pregnant and lactating female patients. * Patients who fail to adhere to follow-up visits or refuse to sign the informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic rhinosinusitis with nasal polyps (CRSWNP) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic rhinosinusitis with nasal polyps (CRSWNP)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.